Video
Dr. Stephanie Berg on latest pivotal trials in mCSPC
Author(s):
Video Player is loading.
Stephanie Berg, MD, Dana-Farber Cancer Institute, discusses the results of the of the PEACE-1 and ARASENS trials. In the phase 3 PEACE-1 trial, adding abiraterone acetate (Zytiga) and prednisone to androgen-deprivation therapy (ADT) and docetaxel improved overall survival (OS) and radiographic progression-free survival in patients with de novo metastatic castration-sensitive prostate cancer. In the phase 3 ARASENS trial, adding darolutamide to standard ADT and docetaxel boosted OS versus ADT/docetaxel alone in patients with metastatic hormone-sensitive prostate cancer.
Related Videos
De novo metastatic prostate cancer: Understanding Biden’s prognosis and treatment
Geoffrey Sonn, MD, on an AI risk mapping tool to predict seminal vesicle invasion
Prostate cancer screening: Expert weighs in after Biden's diagnosis
Clinical Outcomes of Ultra-Low PSA Responses in Patients With mHSPC Receiving Darolutamide Plus ADT
Post Hoc Analysis of ARANOTE; Ultra-Low PSA Responses
Study results affirm effectiveness of evolving prostate cancer therapies
Mitchell Huang, MD, on the link between obesity and pain on transperineal biopsy
Rebecca A. Campbell, MD, discusses citation rates for men and women in the oncology literature
Comparing Trials Studying Treatment Intensification In mHSPC
An Overview of the ARANOTE Trial
Related Content
